Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis

Zhang,Ruitao; Shi,Huirong; Ren,Fang; Liu,Huina; Zhang,Minghui; Deng,Youxing; Li,Xia

doi:10.3892/or.2015.3723

Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis

Authors:
- Ruitao Zhang
- Huirong Shi
- Fang Ren
- Huina Liu
- Minghui Zhang
- Youxing Deng
- Xia Li
View Affiliations

Affiliations: Department of Gynaecology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: January 15, 2015 https://doi.org/10.3892/or.2015.3723
Pages: 1235-1242

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polo-like protein kinase 1 (PLK1), P53 and P21WAF1 are relevant to cell cycle checkpoints and cancer biology. Misregulation of PLK1, P53 and P21WAF1 has been detected in several types of malignant tumors. The present study aimed to clarify the role of PLK1, P53 and P21WAF1 in the prognosis of ovarian cancer. PLK1 and P53 shRNA lentiviral plasmids were transfected into SK-OV-3 cells, respectively. Cell proliferation, apoptosis and invasion were examined by MTT assay, flow cytometry and Matrigel assay, respectively. Survival time of the animals was observed in a xenograft model. Expression levels of PLK1, P53 and P21WAF1 were detected in different ovarian tissues by immunohistochemistry and western blot analysis. Their correlations to the clinicopathologic characteristics of the epithelial ovarian cancer (EOC) cases and their interrelationships were analyzed. Risk factors of prognosis for EOC were determined by logistic regression analysis. The survival time of EOC patients was measured by Kaplan-Meier analysis. After PLK1 or P53 knockdown, proliferation of the SK-OV-3 cells was inhibited, the apoptosis rate was increased, and cell invasion was suppressed in vitro, and the survival time was prolonged in the animals. Expression levels of P53, p-P53 (Ser15), P21WAF1, growth arrest and DNA damage‑inducible gene 45 (GADD45) and 14-3-3σ were upregulated in the SK-OV-3 cells after PLK1 knockdown, but downregulated after P53 knockdown. Higher expression levels of PLK1 and P53 were observed in patients with a higher FIGO stage and worse histological differentiation, but lower P21WAF1 was noted at a higher FIGO stage. Negative correlations were observed between expression of PLK1 and P53 and P53 and P21WAF1 in the EOC cases. PLK1, P53 and P21WAF1 could be used to assess the prognosis of EOC, respectively, but only PLK1 was found to be an independent prognostic factor. The overall survival time of subjects exhibiting PLK1-positive/P53-positive expression and PLK1-positive/P21WAF1-negative expression was obviously shorter than the other patient groups at the end of the follow-up. These results indicate that PLK1 is implicated in ovarian carcinogenesis and may owe its ability to inhibition of the activity of P53. In addition, misregulation of PLK1 coincident with P53 and P21WAF1 in EOC suggests poor prognosis.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Strebhardt K and Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 6:321–330. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kishi K, van Vugt MA, Okamoto K, Hayashi Y and Yaffe MB: Functional dynamics of Polo-like kinase 1 at the centrosome. Mol Cell Biol. 29:3134–3150. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rübsamen-Waigmann H and Strebhardt K: Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene. 14:543–549. 1997. View Article : Google Scholar : PubMed/NCBI
5	Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y and Saji S: Polo-like kinase 1 (PLKI) is overexpressed in primary colorectal cancers. Cancer Sci. 94:148–152. 2003. View Article : Google Scholar : PubMed/NCBI
6	Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, Müller BM, Niesporek S, Dietel M and Denkert C: Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch. 446:442–450. 2005. View Article : Google Scholar : PubMed/NCBI
7	Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M and Kristiansen G: Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate. 60:240–245. 2004. View Article : Google Scholar : PubMed/NCBI
8	Strebhardt K, Kneisel L, Linhart C, Bernd A and Kaufmann R: Prognostic value of pololike kinase expression in melanomas. JAMA. 283:479–480. 2000. View Article : Google Scholar : PubMed/NCBI
9	Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I and Yokoyama S: Expression of polo-like kinase (PLK1) in non-Hodgkin’s lymphomas. Leuk Lymphoma. 46:225–231. 2005. View Article : Google Scholar
10	Yamamoto Y, Matsuyama H, Kawauchi S, Matsumoto H, Nagao K, Ohmi C, Sakano S, Furuya T, Oga A, Naito K and Sasaki K: Overexpression of polo-like kinase 1 (PLKl) and chromosomal instability in bladder cancer. Oncology. 70:231–237. 2006. View Article : Google Scholar
11	Stark GR and Taylor WR: Control of the G₂/M transition. Mol Biotechnol. 32:227–248. 2006. View Article : Google Scholar : PubMed/NCBI
12	Levine AJ: p53, the cellular gatekeeper for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
13	Charrier-Savournin FB, Château MT, Gire V, Sedivy J, Piette J and Dulic V: p21-mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress. Mol Biol Cell. 15:3965–3976. 2004. View Article : Google Scholar : PubMed/NCBI
14	Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
15	Song B, Liu XS and Liu X: Polo-like kinase 1 (Plk1): an unexpected player in DNA replication. Cell Div. 7:32012. View Article : Google Scholar : PubMed/NCBI
16	Yim H and Erikson RL: Polo-like kinase l depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol. 29:2609–2621. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hayashi MT and Karlseder J: DNA damage associated with mitosis and cytokinesis failure. Oncogene. 32:4593–4601. 2013. View Article : Google Scholar : PubMed/NCBI
18	Murray AW: Creative blocks: cell-cycle checkpoints and feedback controls. Nature. 359:599–604. 1992. View Article : Google Scholar : PubMed/NCBI
19	Jeong JH, Kang SS, Park KK, Chang HW, Magae J and Chang YC: p53-independent induction of G1 arrest and p21^WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc. Mol Cancer Ther. 9:2102–2113. 2010. View Article : Google Scholar : PubMed/NCBI
20	Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M and Nakagawara A: Polo-like kinase 1 (Plkl) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem. 279:25549–25561. 2004. View Article : Google Scholar : PubMed/NCBI
21	Ahmad N: Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer. FASEB J. 18:5–7. 2004. View Article : Google Scholar : PubMed/NCBI
22	Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Köbel M, Dietel M and Hauptmann S: Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer. 90:815–821. 2004. View Article : Google Scholar : PubMed/NCBI
23	Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr and Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51:2979–2984. 1991.PubMed/NCBI
24	Skírnisdóttir I and Seidal T: Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I–II) epithelial ovarian cancer. Int J Gynecol Cancer. 21:1024–1031. 2011. View Article : Google Scholar
25	Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL and Bast RC: Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol. 52:232–236. 1994. View Article : Google Scholar : PubMed/NCBI
26	Buchynska LG, Nesina IP, Yurchenko NP, Bilyk OO, Grinkevych VN and Svintitsky VS: Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors. Exp Oncol. 29:49–53. 2007.PubMed/NCBI
27	Terauchi F, Okamoto A, Nagashima T, Kobayashi Y, Moritake T, Yamamoto Y, Takakura S, Iwaki S and Ogura H: Clinical significance of p21^WAF1/CIP1 and p53 expression in serous cystadenocarcinoma of the ovary. Oncol Rep. 14:363–368. 2005.PubMed/NCBI
28	Shi HR and Zhang RT: Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer. Ai Zheng. 28:882–885. 2009.(In Chinese). PubMed/NCBI
29	Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1674–1677. 1998. View Article : Google Scholar : PubMed/NCBI
30	Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB and Siliciano JD: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1677–1679. 1998. View Article : Google Scholar : PubMed/NCBI